TITLE

How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis

AUTHOR(S)
Schachter, Howard M.; Pham, Ba'; King, Jim; Langford, Stephanie; Moher, David
PUB. DATE
November 2001
SOURCE
CMAJ: Canadian Medical Association Journal;11/27/2001, Vol. 165 Issue 11, p1475
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract Background Numerous small clinical trials have been carried out to study the behaviourally defined efficacy and safety of short-acting methylphenidate compared with placebo for attention-deficit disorder (ADD) in individuals aged 18 years and less. However, no meta-analyses that carefully examined these questions have been done. We reviewed the behavioural evidence from all the randomized controlled trials that compared methylphenidate and placebo, and completed a meta-analysis. Methods We searched several electronic sources for articles published between 1981 and 1999: MEDLINE, EMBASE, PsychINFO, ERIC, CINAHL, HEALTHSTAR, Biological Abstracts, Current Contents and Dissertation Abstracts. The Cochrane Library Trials Registry and Current Controlled Trials were also consulted. A study was considered eligible for inclusion if it entailed the following: a placebo- controlled randomized trial that involved short-acting methylphenidate and participants aged 18 years or less at the start of the trial who had received any primary diagnosis of ADD that was made in a systematic and reproducible way. Results We included 62 randomized trials that involved a total of 2897 participants with a primary diagnosis of ADD (e.g., with or without hyperactivity). The median age of trial participants was 8.7 years, and the median "percent male" composition of trials was 88.1%. Most studies used a crossover design. Using the scores from 2 separate indices, this collection of trials exhibited low quality. Interventions lasted, on average, 3 weeks, with no trial lasting longer than 28 weeks. Each primary outcome (hyperactivity index) demonstrated a significant effect of methylphenidate (effect size reported by teacher 0.78, 95% confidence interval [CI] 0.64-0.91; effect size reported by parent 0.54, 95% CI 0.40-0.67). However, these apparent beneficial effects are tempered by a strong indication of publication bias and the lack of robustness of the findings, especially tho...
ACCESSION #
5545074

 

Related Articles

  • Pemoline (Cylert) in the Treatment of Childhood Hyperkinesis. Page, John G.; Janicki, Robert S.; Bernstein, Joel E.; Curran, Charles F.; Michelli, Frank A. // Journal of Learning Disabilities;Oct1974, Vol. 7 Issue 8, p498 

    A controlled, double-blind study using pemoliqe and placebo in the management of hyper-kinetic behavior associated with minimal brain dysfunction is described. Improvement in gross behavior as measured by parent, teacher and physician global evaluations, as well as improvement in cognitive and...

  • The Homeopathic Treatment of Attention Deficit Disorders. Ullman, Dana // Latitudes;2002, Vol. 5 Issue 4, p20 

    Discusses the effectiveness of homeopathic treatment for children with Attention Deficit Disorders (ADD). Short-term side effects associated with drug ritalin used for treating children with ADD; Prescription of homeopathic medicine on individual basis; Comparison of homeopathic treatment with...

  • ATTENTION DEFICIT DISORDER. Leo, Jonathan // Skeptic;2000, Vol. 8 Issue 1, p63 

    Focuses on the use of Ritalin as a drug treatment for children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) in the United States. Percentage of Ritalin consumed by American children; Role of marketing in the acceptance of treating children with mind altering drugs; Absence of...

  • Ritalin and cancer.  // Second Opinion;Jul96, Vol. 6 Issue 7, p2 

    Discusses the lack of scientific evidence showing that the drug Ritalin or methylphenidate causes cancer in children. Use of the drug to treat children with attention-deficit disorder (ADD); Probability that ADD is a wrongly labeled disease; Action to take in using proper lighting to help ADD...

  • Methylphenidate.  // Reactions Weekly;1/24/2009, Issue 1236, p24 

    The article describes the case of a 9-year-old boy with attention-deficit hyperactivity disorder (ADHD) who experienced nocturnal bruxism following treatment with methylphenidate. Clinical improvement of the ADHD symptoms was noted after receiving methylphenidate. However, he developed nocturnal...

  • COULD A SCHOOL FORCE YOUR CHILD TO TAKE RITALIN? Engeler, Amy // Redbook;Oct2001, Vol. 197 Issue 4, p101 

    Relates the experience of Jill and Michael Carroll who fought to take their attention-deficit-disordered child off the drug Ritalin.

  • Dexmethylphenidate - Novartis/Celgene: Focalinâ„¢, D-MPH, D-Methylphenidate Hydrochloride, D-Methylphenidate, Dexmethylphenidate, Dexmethylphenidate Hydrochloride.  // Drugs in R&D;2002, Vol. 3 Issue 4, p279 

    Celgene has developed a chirally pure form of methylphenidate (Ritalin), called dexmethylphenidate [d-methylphenidate, d-methylphenidate hydrochloride, d-MPH; Focalinâ„¢]. The drug has been launched in the USA and is undergoing registration in Canada for the treatment of children with...

  • Stimulant Medication and Reading Performance: Follow-up on Sustained Dose in ADHD Boys with and Without Conduct Disorders. Forness, Steven R.; Swanson, James M.; Cantwell, Dennis P.; Youpa, Daniel; Hanna, Gregory L. // Journal of Learning Disabilities;Feb1992, Vol. 25 Issue 2 

    Examines the sustained effects of methylphenidate on reading performance of children with attention deficit-hyperactivity disorder (ADHD). Formation of two subgroups based on the presence or absence of co-occurring conduct disorders; Effect of stimulant medication on academic performance in...

  • Commentary. Barton, Joanne // Evidence Based Mental Health;Feb2006, Vol. 9 Issue 1, p7 

    The article reports on a study describing data from the first randomized controlled trial examining the effect of atomoxetine in reducing symptoms of attention deficit hyperactivity disorder based on teacher report. The drug has been licensed in Great Britain since 2004. A number of randomized...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics